Blood Tests Decode Alzheimer’s Pathology: A New Era for Immune and Inflammatory Biomarkers
A landmark study in Alzheimer’s & Dementia demonstrates that specific combinations of plasma biomarkers can accurately predict distinct neuropathological features of Alzheimer’s disease (AD) and forecast cognitive decline. Researchers analyzed multivariate patterns of key proteins—including phosphorylated tau (p-tau217, p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP)—across two independent cohorts. They found that unique plasma signatures were strongly associated with amyloid burden in the precuneus, tau pathology in the entorhinal cortex, and hippocampal neurodegeneration. Crucially, models trained on one cohort successfully generalized to the other, validating the robustness of these blood-based predictors for early detection and monitoring of AD progression, offering a scalable and non-invasive alternative to costly neuroimaging.
Study Significance: This research directly intersects with immunology and inflammation through its focus on GFAP, a marker of astrocyte activation, and NfL, indicative of neuronal damage, both central to neuroimmune responses. For professionals in immunology, it underscores the translational power of systemic immune and inflammatory biomarkers in diagnosing complex CNS disorders. The findings pave the way for developing multi-analyte blood panels that could revolutionize patient stratification for immunomodulatory therapies and enhance clinical trial design by providing accessible tools for tracking disease-modifying effects.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
